Glycosylated hemoglobin monitoring of diabetic patients: a pilot study and case report.
Fasting and post-prandial blood glucose values have been found to be not totally representative of daily mean blood glucose concentration. Glycosylated hemoglobin (HbA1c) can be used as a supplemental monitoring device in the management and control of the diabetic patient. A pilot study on HbA1c was performed on a severe insulin dependent diabetic who had fasting glucose levels of 200-400 mg/dl over a six month period. The experimental data indicates that for every 10 mg/dl increase in glucose level, there is a corresponding increase in HbA1c of about .35%. Rate of formation of HbA1c depends on blood glucose concentration and is a slow continuous non-enzymatic process occurring during the normal 120 life span of the red blood cell. As such, it can be a useful monitoring tool.
D001786:Blood Glucose / Q000032:analysis*; D002411:Cation Exchange Resins; D002852:Chromatography, Ion Exchange; D003922:Diabetes Mellitus, Type 1 / Q000097:blood*; D006442:Glycated Hemoglobin / Q000032:analysis*; D006801:Humans; D008297:Male; D008875:Middle Aged
D001786:Blood Glucose; D002411:Cation Exchange Resins; D006442:Glycated Hemoglobin